May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Fremanezumab Cuts Migraine, Depression Burden in Trial

Fremanezumab reduced monthly migraine days and improved depression scores compared with placebo.

Conexiant

May 27, 2025

Rizatriptan Shows No Rapid Relief for Vertigo

A randomized trial found that rizatriptan 10 mg did not significantly reduce vertigo or dizziness within 1 hour during vestibular migraine attacks, though some symptom improvements were seen at 24 hours.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 19, 2025

Ubrogepant Reduces Migraine Symptoms Before Headache

In a randomized trial of nearly 500 patients, ubrogepant reduced early migraine symptoms like fatigue, neck pain, and cognitive fog when taken before headache onset.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 06, 2025

Weight Loss, Hypokalemia Reveal Pituitary Cushing’s Disease

A 75-year-old woman with severe weight loss and low potassium was diagnosed with pituitary Cushing’s disease, challenging assumptions about how the condition typically presents.

Conexiant

May 01, 2025

FDA Approves Intranasal DHE for Acute Migraine Relief

The FDA has approved Atzumi for the acute treatment of migraine with or without aura in adults.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant